

Docket No. 157-47577-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Washington, D.C. 20231

W. Marasco, et al.

Serial No.:

09/522,727

Group No.:

1644

Filed:

March 10, 2000

Examiner

Roark, J.

For:

INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

RECEIVED

RESTRICTION REQUIREMENT

MAR 2 3 2001

Assistant Commissioner for Patents

TECH CENTER 1600/2800

Dear Sir:

In response to the Restriction Requirement dated September 15, 2000, a Petition for a Five Month Extension of Time and payment of fee is enclosed. Applicants elect Group I (claims 1-5 and 6-7), directed to a method of inhibiting an undesirable immune associated reaction, and as species, MHC Class I molecules, with traverse.

REMARKS

Applicants have elected Group I in response to the Restriction Requirement. Applicants have elected as a species MHC Class I molecules, with traverse, on the grounds that examining all of the target molecules at the same time does not present an undue burden in these claims.

In view of the foregoing, applicant respectfully submits that all claims are in condition for allowance. Early and favorable action is requested.

03/21/2001 SSITHIB1 00000012 09522727

01 FC:228

945.00 OP

In the event that any additional fees are required, the PTO is authorized to charge our deposit account No. 50-0850.

Respectfully submitted,

Date: 3/15/01

Ronald I. Eisenstein

(Reg. No.: 30,628) NIXON PEABODY LLP

101 Federal Street Boston, MA 02110 (617) 345-6054